Neurizon Therapeutics Limited has released a press release.
Virtual Investor Briefing Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
In the deck
Earlier from Neurizon Therapeutics
- Preliminary Positive Results for the Treatment of SARS-CoV-2
- Suspension from Official Quotation
- Monepantel Trial Achieves Successful Anti-Cancer Outcome
- PharmAust to Evaluate Monepantel on COVID-19
- Brisbane Animal Hospital Joins Phase II Dog Cancer Trial
Later from Neurizon Therapeutics
- Voluntary Suspension
- Confirmation of Preliminary COVID-19 Results
- Reinstatement to Official Quotation
- Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells
- Appendix 4E & Preliminary Final Report
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics